A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
596
Enrollment
INDUSTRY
Sponsor class
Conditions
Episodic Migraine
Chronic Migraine
Interventions
DRUG:
Atogepant 60 mg
Sponsor
AbbVie